RCPsych General Adult Conference October 2020 – References & Disclosures


  1. Gillett, G., & Saunders, K. E. A. (2019). Remote monitoring for understanding mechanisms and prediction in psychiatry. Current Behavioral Neuroscience Reports, 6(2), 51–56. Link.
  2. Onnela JP, Rauch SL. Harnessing smartphone-based digital phenotyping to enhance behavioral and mental health. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2016;41(7):1691–6. Link.
  3. Insel TR. Digital Phenotyping: Technology for a New Science of Behavior. Jama. 2017;318(13):1215-6. Link.
  4. Gillett, G. A day in the life of a psychiatrist in 2050: Where will the algorithm take us? BJPsych Bulletin, 44(3), 121-123. Link.
  5. Faurholt-Jepsen M, Vinberg M, Frost M, Christensen EM, Bardram JE, Kessing LV. Smartphone data as an electronic biomarker of illness activity in bipolar disorder. Bipolar disorders. 2015;17(7):715-28. Link.
  6. Beiwinkel T, Kindermann S, Maier A, Kerl C, Moock J, Barbian G, et al. Using Smartphones to Monitor Bipolar Disorder Symptoms: A Pilot Study. JMIR mental health. 2016;3(1):e2. Link.
  7. A. Grünerbl et al., “Smartphone-Based Recognition of States and State Changes in Bipolar Disorder Patients,” in IEEE Journal of Biomedical and Health Informatics, vol. 19, no. 1, pp. 140-148, Jan. 2015. Link.
  8. Tsanas A, Saunders KE, Bilderbeck AC, Palmius N, Osipov M, Clifford GD, et al. Daily longitudinal self-monitoring of mood variability in bipolar disorder and borderline personality disorder. Journal of affective disorders. 2016;205:225-33. Link.
  9. Rush AJ, Trivedi MH, Ibrahim HM, Carmody TJ, Arnow B, Klein DN, et al. The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biological psychiatry. 2003;54(5):573-83. Link.
  10. Gillett G, Tomlinson A, Efthimiou O & Cipriani A. Predicting treatment effects in unipolar depression: A meta-review. Pharmacology & Therapeutics. 2020; 212(107557). Link.

Conflict of Interest

Prof Goodwin is a NIHR Emeritus Senior Investigator, holds shares in P1vital and P1Vital products and has served as consultant, advisor or CME speaker in the last 3 years for Compass pathways, Evapharm, Janssen, Lundbeck, Medscape, P1Vital, Sage, Servier. Dr Saunders is supported by the NIHR Oxford Health Biomedical Research Centre. Dr Bilderbeck has received salaries from P1vital Ltd. Dr Palmius holds shares in SmartCare Analytics Ltd. Dr Gillett and Dr McGowan report no competing interests.


The study was supported by the Wellcome Trust through a Centre Grant no. 98,461/Z/12/Z, “The University of Oxford Sleep and Circadian Neuroscience Institute (SCNi)”. This work was also funded by a Wellcome Trust Strategic Award (CONBRIO: Collaborative Oxford Network for Bipolar Research to Improve Outcomes, Reference number 102,616/Z).

Author Contributions

The AMoSS study was conceived and designed by KEAS and GMG. The Android application was developed by NP. Data was collected by KEAS and ACB. The analyses presented here were conceived, designed and performed by GG. The poster is designed, written and presented by GG.


The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health.